Literature DB >> 12746764

Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics.

Maureen M Roden1, Lucienne D Nelson, Tena A Knudsen, Paul F Jarosinski, Judith M Starling, Stacey E Shiflett, Karim Calis, Robert DeChristoforo, Gerald R Donowitz, Donald Buell, Thomas J Walsh.   

Abstract

We investigated the clinical characteristics and treatment of patients with a distinctive triad of acute infusion-related reactions (AIRRs) to liposomal amphotericin B (L-AMB) via single-center and multicenter analyses. AIRRs occurred alone or in combination within 1 of 3 symptom complexes: (1) chest pain, dyspnea, and hypoxia; (2) severe abdomen, flank, or leg pain; and (3) flushing and urticaria. The frequency of AIRRs in the single-center analysis increased over time. Most AIRRs (86%) occurred within the first 5 min of infusion. All patients experienced rapid resolution of symptoms after intravenous diphenhydramine was administered. The multicenter analysis demonstrated a mean overall frequency of 20% (range, 0%-100%) of AIRRs among 64 centers. A triad of severe AIRRs to L-AMB may occur in some centers; most of these reactions may be effectively managed by diphenhydramine administration and interruption of L-AMB infusion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746764     DOI: 10.1086/374553

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

1.  Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis.

Authors:  Glenn Wortmann; Michael Zapor; Roseanne Ressner; Susan Fraser; Josh Hartzell; Joseph Pierson; Amy Weintrob; Alan Magill
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

Review 2.  Primary Cutaneous Coccidioidomycosis: An Update.

Authors:  Irving Llibran Reyna-Rodríguez; Jorge Ocampo-Candiani; Sonia Chavez-Alvarez
Journal:  Am J Clin Dermatol       Date:  2020-10       Impact factor: 7.403

Review 3.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

4.  Invasive fungal infections in acute leukemia.

Authors:  Vijaya R Bhatt; George M Viola; Alessandra Ferrajoli
Journal:  Ther Adv Hematol       Date:  2011-08

5.  An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB).

Authors:  Gourang P Patel; Christopher W Crank; Jerrold B Leikin
Journal:  J Med Toxicol       Date:  2011-03

6.  Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.

Authors:  Nita L Seibel; Aziza T Shad; Ihor Bekersky; Andreas H Groll; Corina Gonzalez; Lauren V Wood; Paul Jarosinski; Donald Buell; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

7.  A clinical pharmacist survey of prophylactic strategies used to prevent adverse events of lipid-associated formulations of amphotericin B.

Authors:  Daniel B Chastain; Rachele L Giles; Christopher M Bland; Carlos Franco-Paredes; Andrés F Henao-Martínez; Henry N Young
Journal:  Infect Dis (Lond)       Date:  2019-02-18

8.  Management of rhinomaxillary mucormycosis with Posaconazole in immunocompetent patients.

Authors:  Sachin Rai; Shikha Yadav; Dinesh Kumar; Vijay Kumar; Vidya Rattan
Journal:  J Oral Biol Craniofac Res       Date:  2016-10-20

9.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

10.  Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT.

Authors:  H J Park; M Park; M Han; B H Nam; K N Koh; H J Im; J W Lee; N-G Chung; B Cho; H-K Kim; K H Yoo; H H Koo; H J Kang; H Y Shin; H S Ahn; Y T Lim; H Kook; C J Lyu; J O Hah; J E Park; Y J Lim; J J Seo
Journal:  Bone Marrow Transplant       Date:  2014-07-07       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.